Compare TROX & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | ALVO |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2012 | N/A |
| Metric | TROX | ALVO |
|---|---|---|
| Price | $5.87 | $3.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $6.36 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.5M | 945.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,898,000,000.00 | N/A |
| Revenue This Year | $6.94 | $13.28 |
| Revenue Next Year | $5.91 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $2.94 |
| 52 Week High | $10.59 | $9.94 |
| Indicator | TROX | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 46.79 |
| Support Level | $5.39 | $3.19 |
| Resistance Level | $8.61 | $3.94 |
| Average True Range (ATR) | 0.37 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 21.86 | 34.21 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.